{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:40:12Z","timestamp":1736314812648,"version":"3.32.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bulcan.2024.06.015","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:25:15Z","timestamp":1725618315000},"page":"S111-S124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Pr\u00e9vention de la rechute des leuc\u00e9mies aigu\u00ebs et syndromes my\u00e9lodysplasiques en post-allogreffe\u00a0: strat\u00e9gies prophylactique et pr\u00e9emptive (SFGM-TC)"],"prefix":"10.1016","volume":"112","author":[{"given":"Val\u00e9rie","family":"Coiteux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Abellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Busquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Coman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Godin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Hermet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambroise","family":"Marcais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Mamez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Souchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2024.06.015_bib0380","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","article-title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis","volume":"56","author":"Jimenez Jimenez","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2024.06.015_bib0385","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/ijms20010228","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment","volume":"20","author":"Rautenberg","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bulcan.2024.06.015_bib0390","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.bulcan.2024.06.015_bib0395","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bulcan.2024.06.015_bib0400","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005\u00a0clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.06.015_bib0405","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic s\u00edndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.06.015_bib0410","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50\u00a0years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.06.015_bib0415","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","article-title":"Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)","volume":"122","author":"Saber","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2024.06.015_bib0420","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2024.06.015_bib0425","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2024.06.015_bib0430","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.3390\/ijms241915019","article-title":"Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation","volume":"24","author":"Liberatore","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11S","key":"10.1016\/j.bulcan.2024.06.015_bib0435","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"12S","key":"10.1016\/j.bulcan.2024.06.015_bib0440","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bulcan.2017.05.009","article-title":"Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)","volume":"104","author":"Yafour","year":"2017","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0445","article-title":"Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques pour les LAM p\u00e9diatriques","author":"Renard","year":"2024","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2024.06.015_bib0450","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2021012411","article-title":"How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy","volume":"141","author":"Biederst\u00e4dt","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2024.06.015_bib0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.2021012412","article-title":"How I treat with maintenance therapy after allogeneic HCT","volume":"141","author":"DeFilipp","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.06.015_bib0460","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.bbmt.2018.12.757","article-title":"ASBMT statement on routine prophylaxis for central nervous system recurrence of acute lymphoblastic leukemia following allogeneic hematopoietic cell transplantation","volume":"25","author":"Sauter","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2024.06.015_bib0465","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3\u00a0trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2024.06.015_bib0470","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.06.015_bib0475","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0480","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2024.06.015_bib0485","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajh.24959","article-title":"Results of a phase 1\u00a0study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant","volume":"93","author":"Sandmaier","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0490","unstructured":"Levis MJ, Hamadani M, Logan B, et al. BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3\u00a0inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023\u00a0Hybrid Congress. Abstract LB2711. Presented June 11, 2023."},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0495","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0500","unstructured":"Guidelines detail. NCCN. Disponible sur\u00a0: https:\/\/www.nccn.org\/guidelines\/guidelines-detail. Accessed September 21th, 2023."},{"key":"10.1016\/j.bulcan.2024.06.015_bib0505","doi-asserted-by":"crossref","first-page":"1095870","DOI":"10.3389\/fonc.2023.1095870","article-title":"Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption","volume":"13","author":"Morin","year":"2023","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.06.015_bib0510","doi-asserted-by":"crossref","first-page":"839e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.bulcan.2024.06.015_bib0515","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3\u00a0randomized study of 5-azacitidine\u00a0maintenance versus observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bulcan.2024.06.015_bib0520","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2024.06.015_bib0525","doi-asserted-by":"crossref","first-page":"10550","DOI":"10.1182\/blood-2022-159336","article-title":"Efficacy of azacitidine post-transplant maintenance for FLT3-negative acute myeloid leukemia and myelodysplastic syndrome","volume":"140","author":"Pasvolsky","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0530","series-title":"Efficacit\u00e9 et tol\u00e9rance de l\u2019azacytidine en traitement prophylactique ou pr\u00e9emptif de la rechute de syndrome my\u00e9lodysplasique ou de leuc\u00e9mie aigu\u00eb my\u00e9lo\u00efde apr\u00e8s une allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques","first-page":"19","author":"Gournay","year":"2021"},{"issue":"3","key":"10.1016\/j.bulcan.2024.06.015_bib0535","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bulcan.2024.06.015_bib0540","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486\u00a0maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"de Lima","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2024.06.015_bib0545","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2024.06.015_bib0550","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12185-023-03595-x","article-title":"Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation","volume":"118","author":"Harada","year":"2023","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0555","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jjco\/hyaa022","article-title":"Prophylactic donor lymphocyte infusion for relapse prevention: a meta-analysis","volume":"50","author":"Poonsombudlert","year":"2020","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.06.015_bib0560","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2024.06.015_bib0565","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00277-021-04494-z","article-title":"Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis","volume":"100","author":"Rettig","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0570","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","article-title":"Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multicenter study","volume":"26","author":"Wang","year":"2012","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2024.06.015_bib0575","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"Yan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0580","article-title":"A retrospective comparison of DLI and gDLI for post-transplant treatment","volume":"12","author":"Lamure","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.bulcan.2024.06.015_bib0585","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1182\/blood-2007-02-072470","article-title":"Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia","volume":"109","author":"Dominietto","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2024.06.015_bib0590","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.bbmt.2016.07.016","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.bulcan.2024.06.015_bib0595","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2024.06.015_bib0600","doi-asserted-by":"crossref","first-page":"839e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bulcan.2024.06.015_bib0605","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","article-title":"Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3\u00a0internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Xuan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0610","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41409-020-01174-w","article-title":"Pre-emptive use of Sorafenib combined with DLI post-HSCT in AML FLT3+: a single center experience","volume":"56","author":"Bruzzese","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2016.12.004","article-title":"Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect","volume":"48","author":"Orti","year":"2017","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.06.015_bib0620","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.06.015_bib0625","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.patbio.2014.05.011","article-title":"Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC. SFGM-TC","volume":"62","author":"Guillaume","year":"2014","journal-title":"Pathol Biol"},{"issue":"1S","key":"10.1016\/j.bulcan.2024.06.015_bib0630","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.bulcan.2018.10.002","article-title":"Donor Lymphocyte Infusions (DLI): guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"106","author":"De Vos","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0635","series-title":"Persistent BCR-ABL1\u00a0clonal hematopoiesis after blast clearance identifies a CML-like subgroup of patients with Philadelphia chromosome-positive (Ph+) ALL: interim results from GRAAPH-2014\u00a0trial","first-page":"S1568","author":"Clappier","year":"2018"},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0640","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.bulcan.2024.06.015_bib0645","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.06.015_bib0650","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0655","doi-asserted-by":"crossref","first-page":"106930","DOI":"10.1016\/j.leukres.2022.106930","article-title":"Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation","volume":"121","author":"Chen","year":"2022","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.bulcan.2024.06.015_bib0660","doi-asserted-by":"crossref","first-page":"813e1","DOI":"10.1016\/j.clml.2020.07.005","article-title":"Effect of prophylactic post-transplant ponatinib administration on outcomes in patients with philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"20","author":"Nanno","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"10.1016\/j.bulcan.2024.06.015_bib0665","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.06.015_bib0670","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.bbmt.2019.09.022","article-title":"Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review","volume":"26","author":"Warraich","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2024.06.015_bib0675","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0680","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","author":"Metheny","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0685","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41409-023-01948-y","article-title":"Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia","volume":"58","author":"Fan","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2024.06.015_bib0690","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s44228-022-00019-1","article-title":"Azacitidine in combination with venetoclax maintenance post-allogeneic hematopoietic stem cell transplantation in T cell acute lymphoblastic leukemia","volume":"5","author":"Hassan","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2024.06.015_bib0695","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2021-152578","article-title":"Comparison of prophylactic and preemptive donor lymphocyte infusion in patients with very high risk acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"138","author":"Yang","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2024.06.015_bib0700","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bmt.1705981","article-title":"A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Lutz","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2024.06.015_bib0705","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/trf.12524","article-title":"Superiority of pre-emptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Tan","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0710","doi-asserted-by":"crossref","first-page":"572918","DOI":"10.3389\/fonc.2020.572918","article-title":"Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"10","author":"Patriarca","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0715","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2024.06.015_bib0720","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.beha.2021.101242","article-title":"Have any strategies in Ph-like all been shown to be effective?","volume":"34","author":"Aldoss","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.06.015_bib0725","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1080\/10428194.2019.1605510","article-title":"Response to single agent dasatinib post-allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1","volume":"60","author":"Aldoss","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1S","key":"10.1016\/j.bulcan.2024.06.015_bib0730","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.bulcan.2018.07.020","article-title":"Clinical pharmacy in a bone marrow and cellular therapy transplantation ward-which methods to put in place: guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)","volume":"106","author":"Forcade","year":"2019","journal-title":"Bull Cancer"},{"issue":"1S","key":"10.1016\/j.bulcan.2024.06.015_bib0735","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.bulcan.2019.06.002","article-title":"A specialist nurse consultation for post-transplant follow-up of patients undergoing allogeneic hematopoietic cell transplantation: recommendations of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"107","author":"Colledani","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.06.015_bib0740","unstructured":"Belaiche S, Balcaen S, Chabanon V, Colledani F, Fournier I, Taque S, et al. L\u2019adh\u00e9sion th\u00e9rapeutique\u00a0: \u00e9tat des lieux en allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques (CSH) dans des services de p\u00e9diatrie et adulte. Rapport de la SFGM-TC. En ligne\u00a0: https:\/\/www.sfgm-tc.com\/harmonisation-des-pratiques\/56-suivi-post-greffe\/178-l-adhesion-therapeutique-etat-des-lieux-en-allogreffe-de-cellules-souches-hematopoietiques-csh-dans-des-services-de-pediatrie-et-adulte."},{"key":"10.1016\/j.bulcan.2024.06.015_bib0745","unstructured":"Direction G\u00e9n\u00e9rale de l\u2019Offre de Soins. DGOS\/R1\/DSS\/1A\/2020\/52\u00a0du 10\u00a0septembre 2020\u00a0relative \u00e0 la gradation des prises en charge ambulatoires r\u00e9alis\u00e9es au sein des \u00e9tablissements de sant\u00e9 ayant des activit\u00e9s de m\u00e9decine, chirurgie, obst\u00e9trique et odontologie ou ayant une activit\u00e9 d\u2019hospitalisation \u00e0 domicile. En ligne\u00a0: https:\/\/sante.gouv.fr\/professionnels\/gerer-un-etablissement-de-sante-medico-social\/financement\/modalites-de-facturation-des-activites-ambulatoires-hospitalieres\/article\/modalites-de-facturation-des-activites-ambulatoires-hospitalieres."},{"issue":"12","key":"10.1016\/j.bulcan.2024.06.015_bib0375","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022\u00a0recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124002777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T18:51:22Z","timestamp":1736275882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124002777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0007455124002777"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9vention de la rechute des leuc\u00e9mies aigu\u00ebs et syndromes my\u00e9lodysplasiques en post-allogreffe\u00a0: strat\u00e9gies prophylactique et pr\u00e9emptive (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}